Citation Tools
PDFRegular and Young Investigator Award Abstracts
Combination Immunotherapies
829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers